Michael P. Schenk

Michael P. Schenk

Regensburg, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Modulation of Pain Perception Through Identifying Emotionally with Music Feedback During Physical Exercise for Patients with Chronic Pain: A Randomized Trial.

Modulation of Pain Perception Through Identifying Emotionally with Music Feedback During Physical Exercise for Patients with Chronic Pain: A Randomized Trial.

Journal: Pain physician

Published: August 04, 2026

Transcutaneous vagus nerve stimulation for postoperative pain reduction in patients with childhood trauma: A randomized controlled pilot study.

Transcutaneous vagus nerve stimulation for postoperative pain reduction in patients with childhood trauma: A randomized controlled pilot study.

Journal: Journal of psychosomatic research

Published: February 27, 2026

Influence of corifollitropin alfa on embryo morphokinetics and fertility treatment outcome.

Influence of corifollitropin alfa on embryo morphokinetics and fertility treatment outcome.

Journal: Frontiers in reproductive health

Published: January 14, 2026

Microbial signatures in follicular fluid and their association with fertilization success.

Microbial signatures in follicular fluid and their association with fertilization success.

Journal: Frontiers in reproductive health

Published: December 22, 2025

Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group.

Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group.

Journal: ESMO open

Published: December 19, 2023

Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).

Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).

Journal: ESMO open

Published: December 07, 2023

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 14, 2023

BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle.

BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle.

Journal: Human reproduction (Oxford, England)

Published: November 13, 2023

Inappropriate proton-pump inhibitor prescribing in primary care - an observational study with quality circles.

Inappropriate proton-pump inhibitor prescribing in primary care - an observational study with quality circles.

Journal: Swiss medical weekly

Published: September 28, 2023

Functional Abdominal Pain Disorders in Children May Be Associated with Food Intolerance/Malabsorption.

Functional Abdominal Pain Disorders in Children May Be Associated with Food Intolerance/Malabsorption.

Journal: Children (Basel, Switzerland)

Published: July 05, 2023

Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?

Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 05, 2023

Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer.

Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer.

Journal: Current oncology (Toronto, Ont.)

Published: April 15, 2023

Showing 1-12 of 72

Last Updated: 09/26/2026